Skip to content
OpenCapital
Get started

Annexon ANNX Quick ratio

Quick ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3×-1.1×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
29.3×+13.3×
Omeros logo
OmerosOMER
3×+1.9×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

quick assets/total current liabilities=6.4×

Based on the most recent quarter.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's quick ratio?
Annexon (ANNX) reported quick ratio of 6.4× in Q1 2026.
How has Annexon's quick ratio changed year-over-year?
Annexon's quick ratio decreased by 20.5% year-over-year, from 8× to 6.4×.
What is the long-term trend for Annexon's quick ratio?
Over 5 years (2020 to 2025), Annexon's quick ratio has grown at a -29.8% compound annual growth rate (CAGR), from 33.3× to 5.7×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.